Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
5
-
Total 13F shares, excl. options
-
466K
-
Shares change
-
+21.8K
-
Total reported value, excl. options
-
$33.4M
-
Value change
-
+$1.56M
-
Number of buys
-
2
-
Number of sells
-
-1
-
Price
-
$71.62
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2023
5 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q4 2023.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 5 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 466K shares
of 108M outstanding shares and own 0.43% of the company stock.
Largest 10 shareholders include FMR LLC (11.5M shares), VANGUARD GROUP INC (9.09M shares), BlackRock Inc. (8.19M shares), WASATCH ADVISORS LP (3.63M shares), Bellevue Group AG (3.07M shares), Avoro Capital Advisors LLC (2.26M shares), STATE STREET CORP (2.22M shares), JPMORGAN CHASE & CO (2.07M shares), GEODE CAPITAL MANAGEMENT, LLC (2M shares), and Deep Track Capital, LP (2M shares).
This table shows the top 5 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.